Nuvectis Pharma, Inc. (NVCT)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Nuvectis Pharma, Inc. (NVCT)
Company Performance

Current Price

as of Oct 16, 2024

$6.60

P/E Ratio

N/A

Market Cap

$123.11M

Description

Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Metrics

Overview

  • HQFort Lee, NJ
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerNVCT
  • Price$6.6+1.69%

Trading Information

  • Market Cap$123.11M
  • Float41.03%
  • Average Daily Volume (1m)83,456
  • Average Daily Volume (3m)87,134
  • EPS-$1.26

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$4.43M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$4.64M
  • EV$88.86M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B9.88
Documents